glp-1 blood brain barrier Glucagon-like peptide-1 (GLP-1), released from the intestine, informs Psychotropic effects of GLP-1R agonists

Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification

I respect Dr

THURSDAY, March 31, 2022 (HealthDay News) -- Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medicine

Seiwerth S, Sikiric P, et al

The immune system shifts dramatically toward Th2 dominance, flooding the skin with interleukin-4 (IL-4), interleukin-13 (IL-13), and interleukin-31 (IL-31)

B12 injections vs tablets at a glance This comparison is a general guide, not a treatment recommendation